Exane Asset Management’s AstraZeneca AZN Stock Holding History

Exane Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.7M	Sell	109,781 -112,688	-51%	-$21.2M	6.39%	5
2026 Q1	$37.6M	Buy	+222,469	New	+$42.9M	7.69%	3

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Exane Asset Management's AZN Position: Q2 2026 in Review

Exane Asset Management reduced its AstraZeneca (AZN) stake by 51% in Q2 2026, selling an estimated $21.2M and leaving 109,781 shares worth $17.7M. The position accounts for 6.39% of the portfolio, ranked #5.

Exane Asset Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $37.6M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Exane Asset Management held 109,781 shares of AstraZeneca worth $17.7M as of Q2 2026.
Exane Asset Management sold 112,688 AstraZeneca shares in Q2 2026, an estimated $21.2M.
AstraZeneca made up 6.39% of Exane Asset Management's portfolio in Q2 2026, its #5 holding.
Exane Asset Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Exane Asset Management's AstraZeneca position peaked at $37.6M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Exane Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.